Fairvalue-Calculator Fairvalue-Calculator
EN DE

Britannia Life Sciences Inc (BLSIF) Fair Value & Analysis

Healthcare · US · Market cap $9.7M

Price$0.0600
Fair Value$0.0730
Upside+21.6%
Quality95/100
Evidence: Low Range $0.0607 – $0.0730

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Britannia Life Sciences Inc (BLSIF) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0730 — implying the stock looks roughly 21.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Britannia Life Sciences Inc. engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is headquartered in Toronto, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Britannia Life Sciences Inc (BLSIF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0730 versus a price of $0.0600 — about +22% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BLSIF?
Our 21-model fair value for Britannia Life Sciences Inc is $0.0730 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0600.
What is the quality score of BLSIF?
Britannia Life Sciences Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.